Table 11.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1994 to 2003

Recipients with Heart Transplants

  Year of Transplant
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Transplants 2,340 2,363 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057
Tx with Antirejection Treatments 934 955 854 871 979 916 900 851 801 654
Antibodies Any in Category 22.7% 20.8% 18.1% 19.3% 21.2% 17.7% 16.3% 15.5% 17.5% 18.5%
ALG 1.8% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 7.7% 8.1% 5.4% 7.9% 7.3% 6.3% 4.6% 3.9% 4.0% 4.6%
OKT3 16.7% 14.5% 13.9% 13.1% 14.9% 7.4% 5.1% 5.8% 6.9% 4.1%
Thymoglobulin 0.0% 0.0% 0.0% 0.1% 0.2% 2.0% 3.8% 4.9% 6.4% 7.5%
Zenapax 0.0% 0.0% 0.0% 0.1% 0.8% 2.5% 3.0% 2.5% 1.5% 2.0%
Simulect 0.0% 0.0% 0.0% 0.0% 0.1% 0.9% 2.0% 0.4% 0.4% 1.4%
Corticosteroids Any in Category 89.4% 92.6% 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.0% 92.5%
Steroids 89.4% 92.6% 88.3% 88.6% 87.9% 91.3% 92.3% 92.7% 92.0% 92.5%
Antimetabolites Any in Category 7.7% 6.6% 5.4% 7.6% 6.5% 4.6% 4.4% 2.0% 2.9% 3.5%
Cytoxan 1.4% 1.8% 1.8% 3.6% 2.5% 2.1% 1.7% 0.5% 0.9% 1.7%
Methotrexate 6.3% 4.9% 3.6% 4.1% 4.3% 2.6% 2.8% 1.5% 2.0% 1.8%


Source: OPTN/SRTR Data as of May 2, 2005.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.